Ask the Expert: Optimal IBD Management for Ulcerative Colitis During COVID-19

Ask the Expert: Optimal IBD Management for Ulcerative Colitis During COVID-19

Ask the Expert: Optimal IBD Management for Ulcerative Colitis During COVID-19

How can we ensure the continuity of care for patients with ulcerative colitis during and after the COVID-19 pandemic?

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    As the COVID-19 pandemic continues, practice gaps for many clinicians providing care for patients with inflammatory bowel disease (IBD) continue to emerge. For those living with IBD, specifically ulcerative colitis, stress and anxiety can be a part of everyday life. During and after the COVID-19 pandemic there are layers of concern that must be addressed for both patients and their providers as we all navigate a host of questions related to ensuring the continuity of care.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    John J. Russell, MD
    Chair, Department of Family Medicine
    Director, Family Medicine Residency
    Abington Memorial Hospital
    Abington, PA

    Consulting Fees: Sanofi Pasteur/GSK
    Speakers Bureau: Sanofi Pasteur 

    Uma Mahadevan, MD
    Professor of Medicine
    Co-Director, UCSF Center for Colitis and Crohn’s Disease
    University of California, San Francisco
    San Francisco, CA

    Consulting Fees: AbbVie, BMS, Gilead, Janssen, Takeda
    Contracted Reasearch: Genentech, Pfizer
    Royalty: UpToDate

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry Fiedel has nothing to disclose.
    • Brian P. McDonough, MD FAAP has nothing to disclose.
    • Florian Reider, MD disclosed consulting fees with Agomab, Allergan, AbbVie, Boehringer-Ingelheim, Celgene, CDISC, Cowen, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Index Pharma, Jannsen, Koutif, Metacrine, Morphic, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Takeda, Techlab, Theravance, Thetis, UCB and contracted research with Boehringer-Ingelheim, Helmsley, Morphic, Pfizer, Pliant, UCB.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Develop practice strategies to preserve continuity of care and ensure effective medication management for patients with ulcerative colitis.
    • Identify best practices for incorporating telemedicine for patients with ulcerative colitis.
    • Define office practices that reduce the risk of COVID-19 transmission for the patient, office staff, and patient care team.
  • Target Audience

    This activity is designed to meet the educational needs of gastroenterology and primary care physicians, nurse practitioners, physician assistants, and nurses.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

    This activity is provided in collaboration with The Crohn’s & Colitis Foundation.

    The Crohn’s & Colitis Foundation is a non-profit, volunteer-fueled organization dedicated to finding cures for Crohn's disease and ulcerative colitis, and improving the quality of life of children and adults affected by these diseases. Since our founding in 1967, the Foundation has played a role in every major breakthrough in IBD research. We have invested more than $350 million into finding the causes, treatments, and cures for Crohn’s disease and ulcerative colitis. And we won’t stop until we realize our vision of a future free from Crohn’s and Colitis. The Foundation offers healthcare providers a wide range of education and resources to support and improve your understanding of inflammatory bowel disease (IBD). These provider education programs keep the patient at the center by combining training in the current standard of care with the latest in cutting-edge research. Our comprehensive educational resources cover a range of topics from initial diagnosis and treatment to ongoing IBD management. If you are a healthcare provider, we also encourage you to become a Professional Member of the Crohn's & Colitis Foundation to establish yourself as a leader and specialist in Crohn's disease and ulcerative colitis.

  • Commercial Support

    This activity is supported by an independent educational grant from Pfizer Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Publish Date

    Release Date: 06/10/2020

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free